This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities over the past seven years.
Gilead Sciences is a top pharmaceutical company based in California, USA
Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen
Partnering was down on the previous week in terms of number of deals, however a number of deals of financial significance were announced
Sorry, your search returned no results.
Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.
Gilead and Teva Pharmaceuticals, two top big pharma companies, have reached a settlement agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate).
Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.
Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.